Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.32 |
| ▸ | FGF1 | P05230 | 1/20 | 0.31 |
| ▸ | FGF2 | P09038 | 1/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20987120 | 0.87 | F10 (0.42) | F10AMDHD2CA2F2SERPINC1 | |
| SCHEMBL13286928 | 0.87 | F10 (0.42) | F10AMDHD2CA2F2SERPINC1 | |
| SCHEMBL7209918 | 0.87 | F10 (0.42) | F10AMDHD2CA2F2SERPINC1 | |
| SCHEMBL16728926 | 0.87 | F10 (0.42) | F10AMDHD2CA2F2SERPINC1 | |
| SCHEMBL7209912 | 0.87 | F10 (0.42) | F10AMDHD2CA2F2SERPINC1 | |
| SCHEMBL1009127 | 0.87 | F10 (0.42) | F10AMDHD2CA2F2SERPINC1 | |
| SCHEMBL21067663 | 0.87 | F10 (0.42) | F10AMDHD2CA2F2SERPINC1 | |
| SCHEMBL29535532 | 0.82 | F10 (0.48) | F10F2SERPINC1FGF1FGF2 | |
| SCHEMBL29534894 | 0.79 | F10 (0.43) | F10AMDHD2CA2F2SERPINC1 | |
| SCHEMBL16729027 | 0.77 | F10 (0.41) | F10F2SERPINC1FGF1FGF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346894-B2 | Polysaccharides comprising two antithrombin III-binding sites, preparation thereof and use thereof as antithrombotic medicaments | SANOFI (FR) | 2016-05-24 | — | — | US | disclosed |
| US-20140031316-A1 | POLYSACCHARIDES COMPRISING TWO ANTITHROMBIN III-BINDING SITES, PREPARATION THEREOF AND USE THEREOF AS ANTITHROMBOTIC MEDICAMENTS | SANOFI (FR) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031316-A1 | POLYSACCHARIDES COMPRISING TWO ANTITHROMBIN III-BINDING SITES, PREPARATION THEREOF AND USE THEREOF AS ANTITHROMBOTIC MEDICAMENTS | SERPINC1, F13B, F12 | F10 16/4885AMDHD2 1295/4885CA2 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.